启迪药业
(000590)
| 流通市值：29.28亿 | | | 总市值：29.29亿 |
| 流通股本：2.39亿 | | | 总股本：2.39亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 142,437,429.61 | 65,220,251.47 | 343,208,128.81 | 216,231,190.77 |
| 营业收入 | 142,437,429.61 | 65,220,251.47 | 343,208,128.81 | 216,231,190.77 |
| 二、营业总成本 | 170,030,690.76 | 81,374,066.11 | 371,218,456.86 | 245,156,662.17 |
| 营业成本 | 78,434,251.57 | 34,274,422.07 | 182,536,813.91 | 116,313,531.97 |
| 税金及附加 | 3,375,405.44 | 1,606,393.25 | 8,052,681.56 | 5,540,969.54 |
| 销售费用 | 33,870,611.95 | 17,241,678.39 | 69,432,829.81 | 48,318,651.88 |
| 管理费用 | 44,446,076.64 | 24,150,788.67 | 95,570,825.39 | 63,437,965.33 |
| 研发费用 | 8,292,249.34 | 3,367,126.57 | 13,165,981.32 | 9,725,247.73 |
| 财务费用 | 1,612,095.82 | 733,657.16 | 2,459,324.87 | 1,820,295.72 |
| 其中:利息费用 | 1,907,967.66 | 899,884.16 | 3,661,916.25 | 2,836,115.07 |
| 其中:利息收入 | 339,545.26 | 181,997.23 | 1,271,591.37 | 1,064,857.34 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | -871,950.28 | - |
| 加:投资收益 | 36,284.33 | 161,696.82 | 372,373.55 | 71,750.14 |
| 资产处置收益 | 3,444,349.77 | -118,765.88 | 4,780.83 | -6,342.95 |
| 资产减值损失(新) | -640.48 | - | -119,237,884.73 | 11,235.8 |
| 信用减值损失(新) | 6,537,613.08 | 27,813.76 | -26,901,757.6 | -628,608.75 |
| 其他收益 | 2,519,531.35 | 967,625.23 | 5,964,521.81 | 4,504,576.02 |
| 四、营业利润 | -15,056,123.1 | -15,115,444.71 | -168,680,244.47 | -24,972,861.14 |
| 加:营业外收入 | 200,501.22 | 14,004.31 | 48,374,373.54 | 30,682.6 |
| 减:营业外支出 | 109,602.54 | 91,557.83 | 1,832,674.27 | 793,574.08 |
| 五、利润总额 | -14,965,224.42 | -15,192,998.23 | -122,138,545.2 | -25,735,752.62 |
| 减:所得税费用 | 2,298,316.8 | 1,068,244.03 | 5,091,507.88 | 2,497,698.76 |
| 六、净利润 | -17,263,541.22 | -16,261,242.26 | -127,230,053.08 | -28,233,451.38 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -17,263,541.22 | -16,261,242.26 | -127,230,053.08 | -28,233,451.38 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -17,170,056.39 | -16,256,161.33 | -125,471,522.88 | -28,454,466.79 |
| 少数股东损益 | -93,484.83 | -5,080.93 | -1,758,530.2 | 221,015.41 |
| 扣除非经常损益后的净利润 | -22,652,173.34 | -17,089,914.38 | -169,817,012.09 | -31,883,841.54 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.07 | -0.07 | -0.52 | -0.12 |
| (二)稀释每股收益 | -0.07 | -0.07 | -0.52 | -0.12 |
| 九、综合收益总额 | -17,263,541.22 | -16,261,242.26 | -127,230,053.08 | -28,233,451.38 |
| 归属于母公司股东的综合收益总额 | -17,170,056.39 | -16,256,161.33 | -125,471,522.88 | -28,454,466.79 |
| 归属于少数股东的综合收益总额 | -93,484.83 | -5,080.93 | -1,758,530.2 | 221,015.41 |
| 公告日期 | 2025-08-27 | 2025-04-28 | 2025-03-28 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |